These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3136793)

  • 21. Protein modification during anti-viral heat-treatment bioprocessing of factor VIII concentrates, factor IX concentrates, and model proteins in the presence of sucrose.
    Smales CM; Pepper DS; James DC
    Biotechnol Bioeng; 2002 Jan; 77(1):37-48. PubMed ID: 11745172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of TT virus DNA in plasma-derived clotting factor concentrates.
    Yokozaki S; Fukuda Y; Nakano I; Katano Y; Toyoda H; Takamatsu J
    Blood; 1999 Nov; 94(10):3617. PubMed ID: 10610120
    [No Abstract]   [Full Text] [Related]  

  • 23. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Improvement in anti-hemophilic preparations and its problems. 2. Inadequacy of the heat treatment of factor concentrates on the inactivation of non-A, non-B hepatitis virus].
    Inagaki M; Osano M
    Rinsho Ketsueki; 1988 May; 29(5):635-9. PubMed ID: 3145994
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatitis A transmission by factor IX concentrates: control by severe dry heat treatment at 80 degrees C.
    Roberts P; Feldman P
    Vox Sang; 1997; 73(3):189-90. PubMed ID: 9358623
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates.
    Watson HG; Ludlam CA; Rebus S; Zhang LQ; Peutherer JF; Simmonds P
    Br J Haematol; 1992 Apr; 80(4):514-8. PubMed ID: 1581236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
    Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
    Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
    [No Abstract]   [Full Text] [Related]  

  • 28. [Transmission of hepatitis C by factor concentrates].
    Aguilar C; Lucía JF
    Sangre (Barc); 1996 Apr; 41(2):160-1. PubMed ID: 9045360
    [No Abstract]   [Full Text] [Related]  

  • 29. Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour.
    Mannucci PM; Zanetti AR; Colombo M
    Br J Haematol; 1988 Apr; 68(4):427-30. PubMed ID: 3132199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Transmission of the human immunodeficiency virus by a dry heat-treated Factor VIII concentrate?].
    Weisser J
    Klin Padiatr; 1988; 200(5):375-9. PubMed ID: 3141670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. No detectable alterations in immunogenicity following terminal severe dry-heat treatment of high-purity factor VIII (Liberate) and factor IX (HP9) concentrates.
    MacGregor IR; McLaughlin LF; MacGregor MC; Prowse CV; Pepper DS
    Vox Sang; 1995; 69(4):319-27. PubMed ID: 8751301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII cryoprecipitate and hepatitis risk.
    Gabra GS; Crawford RJ; Mitchell R
    Lancet; 1982 Nov; 2(8309):1220. PubMed ID: 6128524
    [No Abstract]   [Full Text] [Related]  

  • 33. [HTLV-III antibodies and immunologic changes in hemophilic children. Prevalence of HTLV-III antibodies in hemophilic children and their relatives living in the same household].
    Zenz W; Muntean W; Teubl I; Beaufort F; Heinz FX
    Padiatr Padol; 1987; 22(1):33-41. PubMed ID: 3108827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 36. Safer factor VIII and IX.
    Lancet; 1986 Aug; 2(8501):255-6. PubMed ID: 2874281
    [No Abstract]   [Full Text] [Related]  

  • 37. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin.
    Kernoff PB; Lee CA; Karayiannis P; Thomas HC
    Br J Haematol; 1985 Jul; 60(3):469-79. PubMed ID: 3925981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 39. Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform.
    Mannucci PM; Colombo M; Rodeghiero F
    Lancet; 1985 Nov; 2(8462):1013. PubMed ID: 2865484
    [No Abstract]   [Full Text] [Related]  

  • 40. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.